Chemotherapy adjuvant<unk>  is used therapeutically to reduce the incidence of haemorrhagic cystitis and haematuria when a patient receives ifosfamide or cyclophosphamide for cancer chemotherapy. These two anticancer agents, in vivo, may be converted to urotoxic metabolites, such as acrolein.<unk>  assists to detoxify these metabolites by reaction of its sulfhydryl group with α,β-unsaturated carbonyl containing compounds such as acrolein. This reaction is known as a Michael addition.<unk>  also increases urinary excretion of cysteine. Other Outside North America,<unk>  is also used as a mucolytic agent, working in the same way as acetylcysteine; it is sold for this indication as Mistabron and Mistabronco.
Mesna
Frax
Welt 
Bibic
Favus
Tar 
Erdosteine
Lisp